It's starting to feel a little like "Let's Make a Deal." 

Your Twitter feed no doubt blew up this morning when AbbVie (ABBV - Get Report) agreed to pay for struggling Botox maker Allergan (AGN - Get Report) .

Wall Street voices skepticism on AbbVie's $ABBV aggressive Allergan $AGN acquisition - @KevinCurranRM https://t.co/ZKweBGuVaO

— Real Money (@realmoney) June 25, 2019

The price tag? The takeover bid comes in at a cool $63 billion.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015. Read Real Money's take here.

It's just the latest in a long string of deals for 2019.

Watch the video for an M&A round-up.

Related. Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Shares of Botox Maker Allergan Get a Lift